Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan 1;109(1):93-9.
doi: 10.1002/cncr.22366.

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma

Dean A Fennell  1 , Jeremy P C Steele, Jonathan Shamash, Marie T Evans, Paula Wells, Michael T Sheaff, Robin M Rudd, Justin Stebbing
Affiliations
Free article

Efficacy and safety of first- or second-line irinotecan, cisplatin, and mitomycin in mesothelioma

Dean A Fennell et al. Cancer. .
Free article

Abstract

Background: Malignant pleural mesothelioma (MPM) is a rapidly progressive lethal tumor. Treatment options remain limited and the outcome in recurrent disease is poor.

Methods: A Phase II open-label noncomparative study was conducted to assess the safety and efficacy of the triplet combination irinotecan, cisplatin, and mitomycin-C (IPM) chemotherapy in untreated patients and in those with previous exposure to chemotherapy.

Results: In 62 patients an objective response rate of 25% was observed. In the first-line setting progression-free survival measured 6.4 months (95% confidence interval [CI]: 4.5-7.3) and overall survival was 10.8 months (95% CI: 7.9-13.7). In the second-line setting progression-free survival was 7.3 months (95% CI: 3.4-11.2) and overall survival was also 7.3 months (95% CI: 4.8-9.8). Psychosocial well-being improved during chemotherapy and the main toxicity observed was neutropenia (40%).

Conclusions: IPM appeared to have a reasonable response rate with an acceptable toxicity profile in the first- and second-line treatment of MPM.

PubMed Disclaimer

MeSH terms

LinkOut - more resources